COLORADO SPRINGS, Colo., March 4, 2010 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTCBB:CBIS), a pharmaceutical cannabis company in the U.S., announced today that it has set its second FDA drug target on the $20 Billion “Chronic Pain” market targeting the huge need for safe, non-addictive, non-lethal cannabis based medications. Its first step is to launch a new survey of cannabis use by chronic pain patients, which will compile additional first hand information from all chronic pain suffers for additional data.
